RG3039

RG3039 (PF-06687859) is an orally bioavailable and brain-penetrant DcpS inhibitor with an IC50 of 0.069 nM.

Product Specifications

CAS Number

[1005504-62-0]

Product Name Alternative

PF-06687859

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/RG3039.html

Concentration

10mM

Purity

99.30

Solubility

DMSO : 5 mg/mL (ultrasonic; warming; heat to 60°C) |H2O : < 0.1 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

NC1=NC(N)=C2C(OCC3CCN(CC4=C(Cl)C=CC=C4Cl)CC3)=CC=CC2=N1

Molecular Formula

C21H23Cl2N5O

Molecular Weight

432.35

Precautions

H302, H315, H319, H335

References & Citations

[1]Gopalsamy A, et al. Design of Potent mRNA Decapping Scavenger Enzyme (DcpS) Inhibitors with Improved Physicochemical Properties To Investigate the Mechanism of Therapeutic Benefit in Spinal Muscular Atrophy (SMA) . J Med Chem. 2017 Apr 13;60 (7) :3094-3108.|[2]Gogliotti RG, et al. The DcpS inhibitor RG3039 improves survival, function and motor unit pathologies in two SMA mouse models. Hum Mol Genet. 2013 Oct 15;22 (20) :4084-101.|[3]Van Meerbeke J, et al. The DcpS inhibitor RG3039 improves motor function in SMA mice. Hum Mol Genet. 2013 Oct 15;22 (20) :4074-83.